U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07036172) titled 'Efficacy and Safety of Semaglutide Injection Vs WEGOVY(R) in Chinese Obese Patients' on June 16.
Brief Summary: This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY(R) in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY(R) injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that inv...